Robust and low-cost ELISA based on IgG-Fc tagged recombinant proteins to screen for anti-SARS-CoV-2 antibodies

The development of new diagnostic assays become a priority for managing COVID-19. To this aim, we presented here an in-house ELISA based on the production of two major recombinant and high-quality antigens from SARS-CoV-2. Full-length N and S-RBD fragment proteins fused to mouse IgG2a-Fc were produc...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunol Methods
Auteurs principaux: Frumence, Etienne, Lebeau, Grégorie, Viranaicken, Wildriss, Dobi, Anthony, Vagner, Damien, Lalarizo Rakoto, Mahary, Sandenon Seteyen, Anne-Laure, Giry, Claude, Septembre-Malaterre, Axelle, Raffray, Loïc, Gasque, Philippe
Format: Artigo
Langue:Inglês
Publié: Elsevier B.V. 2021
Sujets:
Technical Note
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8152238/
https://ncbi.nlm.nih.gov/pubmed/34051226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jim.2021.113082
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires